T-DXd in HER2 – Expressing Biliary Tract Cancer

Yakup Ergün, Medical Oncologist at Batman World Hospital, shared on X about a recent paper by Akihiro Ohba et al. titled “Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial” published in Journal Of Clinical Oncology.

Authors: Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda et al.

“T-DXd in HER2 – Expressing Biliary Tract Cancer (HERB: NCCH1805):

Single-Arm, Phase II Trial

32 pts previously treated, 5.4mg/kg

ORR
HER2+36.4%
HER2-Low12.5%

ILD 25% (G5 6%)

ILD requires careful monitoring and early intervention!”

Source: Yakup Ergün/X